Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to take steps to monitor the potential impact of the ban on puberty blockers on (a) the mental health and (b) suicide rates among trans patients under the age of 18.

The emergency banning order, restricting the sale or supply of puberty blockers, was introduced by the previous government. The Order enables those who were already on a course of treatment with Gonadotrophin-Releasing Hormone Analogues, before 3 June 2024 from a UK based private or National Health Service provider, to continue to have them supplied. Those who were already on a course of treatment prescribed by an EEA or Switzerland-registered prescriber can legally switch to a UK based prescriber to continue their treatment.

We will continue to monitor the impact of the emergency order, including on mental health and suicide. All child deaths undergo a multi-agency review by a Child Death Overview Panel and that information is reported to the National Child Mortality Database. There is a monthly exercise by NHS officials to check the waiting list against NHS records to identify any deaths.

Professor Louis Appleby, Chair of the National Suicide Prevention Strategy Advisory Group, has examined evidence for a large rise in suicides claimed by campaigners. His paper, which was published on 19 July 2024, concluded that the data does not support the claim that there has been a large rise in suicide in young gender dysphoria patients at the Tavistock clinic.

This government has committed to implementing the expert recommendations of the Cass Review to ensure that young people presenting to the NHS with gender dysphoria are receiving appropriate and high-quality care. That is why NHS England and the National Institue of Health and Care Research – the research arm of the department – are working together to commission a study into the potential benefits and harms of puberty suppressing hormones as a treatment option for children and young people with gender incongruence. The study team is now in place and are finalising their application for funding which will be assessed by an independent scientific review study ahead of the commencement of wider approvals, including ethics, and set up.

Children and young people who are unable to access puberty blockers when they have previously done so are strongly advised to meet with their clinician. We expect clinicians to be working with impacted patients to consider what the best care for them is going forward. We understand some children and young people may be concerned or distressed by the changes. If they are already under the care of a Children and Young People’s mental health provider or Child and Adolescent Mental Health Services, they can contact their team for advice. If they are not, their general practice team will be able to assess whether further referrals for mental health support are required.

Professor Appleby’s paper is available at the following link:

https://www.gov.uk/government/publications/review-of-suicides-and-gender-dysphoria-at-the-tavistock-and-portman-nhs-foundation-trust